STOCK TITAN

Keros Therapeutics, Inc. (KROS) Net Income by Year

KROS

Keros Therapeutics, Inc. reported $87.0M in net income in fiscal year 2025. This represents an increase of 146.4% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $83.2M net loss. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Keros Therapeutics, Inc. has filed alongside them.

FY2025 annual
Net Income $87.0M
YoY +146.4%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

KROS Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-K
Net Income-$83.2M$87.0M+146.4%-$187.4M-22.5%-$153.0M-46.2%-$104.7M-78.2%-$58.7M-29.5%-$45.4M-267.7%-$12.3M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

KROS Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$28.7M+6.5%-$23.7M-116.0%-$23.5M+49.0%-$7.3M+86.3%-$30.7M+32.2%$148.5M+444.3%-$46.0M-$53.0M-34.3%-$45.3M-20.7%-$43.1M-20.4%N/A-$39.4M-67.8%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Keros Therapeutics, Inc. financials

Frequently Asked Questions

What was Keros Therapeutics, Inc.'s net income in fiscal year 2025?

Keros Therapeutics, Inc. reported $87.0M in net income in fiscal year 2025.

How fast is Keros Therapeutics, Inc.'s net income growing?

Keros Therapeutics, Inc. (KROS) net income rose by 146.4% year over year, from -$187.4M to $87.0M in fiscal year 2025.

What is Keros Therapeutics, Inc.'s net income over the last twelve months?

Keros Therapeutics, Inc. (KROS) reported a $83.2M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 7 fiscal years this page covers, Keros Therapeutics, Inc. (KROS) net income went from -$12.3M in fiscal year 2019 to $87.0M in fiscal year 2025.

Keros Therapeutics, Inc. (KROS) reported -$28.7M in net income in Q2 2026. This represents an increase of 6.5% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Keros Therapeutics, Inc. (KROS) reported on that line in every period on record.